ARCHIVES

CMS Looks At Coverage of Two Agents Approved on Surrogate Endpoints

This article is from The Cancer Letter archive.

Vol. 29 No. 08 | February 21, 2003

Download PDF Visit The Full Archive

Related Articles

Ten-Year Breast Cancer Survival Improved In Past 60 Years, MD Anderson Study Finds

October 29, 2010

Letrozole Cuts Risk Of Breast Cancer Recurrence Even After Tamoxifen Use

March 28, 2008

Two Avastin Trials Show OS Benefit In Advanced Disease

August 27, 2010

Data Presented At Scientific Meetings Can Have Impact On Patient Treatment

March 31, 2006

Gleevec Approval Sets Record For FDA Review: 73 Days

May 25, 2001

NIH Forming Special Emphasis Panel To Review Clinical Oncology Grants

September 18, 1998